About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

Breast Cancer Chemoprevention

  • Basics

Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer
U. Veronesi, L. Mariani, A. Decensi, F. Formelli, T. Camerini, R. Miceli, M. G. Di Mauro, A. Costa, E. Marubini, M. B. Sporn and G. De Palo. Annals of Oncology. Volume 17, Number 7: p. 1065-1071, July, 2006.

Statins reduce breast cancer risk: a case control study in US female veterans
R. Kochhar, V. Khurana, H. Bejjanki, G. Caldito, C. Fort American Society of Clinical Oncologists. (abstract # 514), May 2005. (Annual conference proceedings abstract)

Factor V Leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen
J. E. Garber, S. Halabi, E. Kaplan, S. Edge, L. Dressler, E. Paskett, N. Berliner, Cancer and Leukemia Group. American Society of Clinical Oncologists. (abstract # 508), May 2005. (Annual conference proceedings abstract)

Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
SD Solomon, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators. New England Journal of Medicine. Volume 17, Number 11: p. 1071-80, March 2005

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Anthony Howell, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group. Lancet. Volume 365, Number 9453: p. 60-62, January 2005.

Breast Cancer and Nonsteroidal Anti-Inflammatory Drugs
Randall E. Harris, Rowan T. Chlebowski, Rebecca D. Jackson, David J. Frid, Joao L. Ascenseo, Garnet Anderson, Aimee Loar, Rebecca J. Rodabough, Emily White and Anne McTiernan. Cancer Research. Volume: 63, Issue 18: p. 6096-6101, September 15, 2003

A gonadotropin-releasing hormone agonist (GnRHA)-based chemoprevention regimen that reduces mammographic density in BRCA carriers while maintaining good quality of life (QOL), bone density and reproductive options
J. Weitzel, S. Buys, M. C. Pike, A. Daniels, G. Ursin, J. R. Daniels, D. J. MacDonald, K. R. Blazer, D. V. Spicer. American Society of Clinical Oncologists. Volume 22: p. 94, (abstract # 374), June 2003. (Annual conference proceedings abstract)

Effects of Tamoxifen on Benign Breast Disease in Women at High Risk for Breast Cancer
Elizabeth Tan-Chiu, Jiping Wang, Joseph P. Costantino, Soonmyung Paik, Cheryl Butch, D. Lawrence Wickerham, Bernard Fisher, Norman Wolmark. Journal of the National Cancer Institute. Volume 95, Number 4: p. 302-307, February 2003. (Full text)

Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Steven A. Narod, Marie-Pierre Dubé, Jan Klijn, Jan Lubinski, Henry T. Lynch, Parviz Ghadirian, Diane Provencher, Ketil Heimdal, Pal Moller, Mark Robson, Kenneth Offit, Claudine Isaacs, Barbara Weber, Eitan Friedman, Ruth Gershoni-Baruch, Gad Rennert, Barbara Pasini, Theresa Wagner, Mary Daly, Judy E. Garber, Susan L. Neuhausen, Peter Ainsworth, Hakan Olsson, Gareth Evans, Michael Osborne, Fergus Couch, William D. Foulkes, Ellen Warner, Charmaine Kim-Sing, Olufunmilayo Olopade, Nadine Tung, Howard M. Saal, Jeffrey Weitzel, Sofia Merajver, Marion Gauthier-Villars, Helena Jernstrom, Ping Sun, Jean-Sebastien Brunet. Journal of the National Cancer Institute. Volume 94, Number 23: p. 1773-1779, December 2002.

Tamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2
Mary-Claire King, PhD; Sam Wieand, PhD; Kathryn Hale, BS; Ming Lee, PhD; Tom Walsh, PhD; Kelly Owens, PhD; Jonathan Tait, MD, PhD; Leslie Ford, MD; Barbara K. Dunn, MD, PhD; Joseph Costantino, DrPH; Lawrence Wickerham, MD; Norman Wolmark, MD; Bernard Fisher, MD. Journal of the American Medical Association. Volume 286: p. 2251-2256, November 2001.

Tamoxifen and risk of contralateral breast cancer in and mutation carriers: a case-control study
Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H, Hereditary Breast Cancer Clinical Study Group. Lancet. Volume 356, Issue 9245: p. 1876-81, December 2000.

Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
Bernard Fisher, Joseph P. Costantino, D. Lawrence Wickerham, Carol K. Redmond, Maureen Kavanah, Walter M. Cronin, Victor Vogel, André Robidoux, Nikolay Dimitrov, James Atkins, Mary Daly, Samuel Wieand, Elizabeth Tan-Chiu, Leslie Ford, Norman Wolmark, and other National Surgical Adjuvant Breast and Bowel Project Investigators. Journal of the National Cancer Institute. Volume 90, Number 18: p. 1371-1388, September 1998.


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org